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• Spinal deformity, with progressive kypho-scoliosis or
dorsal kyphosis with attenuation of lumbar lordosis;
• Deformity of sternum-clavicular bony structures, with
subsequent headache, neck and shoulder pain, hand
paresthesia and breath difficulties;
• Sleep disorders, difficulty in dressing and accomplish-
ing certain movements.
An ulnar neuropathy has also been described in women
with severe breast hypertrophy, who report paresthesia in
the ulnar nerve territory.
Moreover, psychological problems can negatively in-
fluence social and sexual life. Reduction mammaplasty has
to be considered, in such a clinical picture, the best thera-
peutic approach for these patients.
NORMAL ANATOMY
The breast is a pair and symmetric skin relief situated on
the anterior surface of the thorax, between the third and the
seventh rib, extending from the parasternal line to the mid-
dle axillary line. The nipple should lie above the inframam-
mary fold and is usually level with the fourth rib.
The mammary gland, being derived from the ectoderm,
is contained in the superficial layer of the subcutaneous tis-
sue, between the superficial fascia and the skin. It is an-
chored to the pectoralis major fascia by the suspensory lig-
aments first described by Cooper in 1840, which run from
the deep fascia throughout the parenchyma to attach to the
dermis of the skin. An horizontal fibrous septum originates
from the pectoral fascia along the level of the fifth rib, di-
viding the mammary gland in a cranial and a caudal part. It
acts as a suspensory system, and as a guiding structure for
vascular and nerve supply.
Vascular anatomy
The blood supply to the breast relies on two main pedicles:
the superolateral pedicle of the external mammary artery
(branch of the lateral thoracic artery) and the glandular
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The idea of beauty and “normality” of breast hasundergone many changes over the years, depend-ing upon customs and society. To date, breasts areconsidered normals when symmetric, with a vol-
ume ranging between 250 and 400 ml, and the nipple-areo-
la complex situated above the inframammary fold.
Morphologic differences exist between different races,
that also depend on weight, age, height and thoracic structure
of the patient. Therefore, it is rather hard to establish univer-
sal anatomic and clinic criteria to mark a clear-cut limit be-
tween normality and hypertrophy of the mammary glands.
However clinical considerations permit to evaluate the
presence and gradation of hypertrophy in a particular pa-
tient. In this regard, clinical important features are:
• Breast volume;
• The distance between the middle point of the clavicle
and the nipple-areola complex;
• The distance between the inframammary fold and the
nipple-areola complex.
In one of the most accepted classifications, considering
standard breast volume as ranging between 250 and 400 ml,
hypertrophy is defined mild for volumes between 400 and
600 ml, moderate between 600 and 800 ml, severe between
800 and 1000, gigantomastia over 1000 ml (Figure 19-1).
A distance of 16 to 21 cm between the mid-clavicular
point and the nipple-areola complex is considered “nor-
mal”, but this value is considerably influenced by patient
height. Distance between the nipple-areola complex and
the inframammary fold is usually 5-8 cm.
Macromastia or mammary hypertrophy is a deforming,
disabling and painful condition characterized by an en-
largement of various degree of one or both breasts. Besides
being a significant aesthetic defect, this condition causes
physical and psychological problems.
Clinical manifestations associated to mammary hyper-
trophy are:
• Intertriginous lesions induced by friction of the breast
against thorax and by the bra at the level of the shoul-
ders; these lesions are worsen by perspiration, which
predisposes to infections by Candida, increasing irrita-
tion of reddened areas;
branches of the thoracodorsal artery, and the internal pedi-
cle of the internal mammary artery, with its perforators
from the second to sixth interspace. Their superficial
branches anastomose in the subdermal plexus, supplying
the breast skin.
A large perforator of the internal mammary artery
emerges from the second or third interspace, running about
1 cm deep to the skin, and supplying a superior pedicle for
the nipple-areola complex. Perforators from the third to
sixth interspace also present a superficial course, and sup-
ply a medially based pedicle. The lateral pedicle relies on
the lateral thoracic system, that is usually found 2 or 3 cm
deep to the skin at the level of the inframammary fold.
Innervation
Sensory innervation of the breast is mainly derived from
the anterolateral and anteromedial branches of thoracic in-
tercostal nerves T3-T5.
Innervation of the nipple-areola complex depends on the
lateral branch of the fourth intercostal nerve, with its superfi-
cial and deep branch. The first one supplies a lateral pedicle,
while the deep branch can sometimes be preserved with an
inferior or central pedicle. The anterior branch of the third in-
tercostal nerve also contributes to the sensitivity of the nipple-
areola complex; it takes a superficial course within the sub-
cutaneous tissue and terminates at the medial areolar border.
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Fig. 19-1. A-B, Moderate breast hypertrophy. C-D, Severe breast hypertrophy. E-F: Gigantomastia.
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PATHOGENESIS
The breast is the target organ for numerous hormones,
which are responsible for mammogenesis, lactogenesis and
galactogenesis.
Some authors claim that alterations in endocrine
arrangement concerning estrogens, progesterone, prolactin
LH, FSH, could represent the “primum movens” of mam-
mary hypertrophy. Others attribute to those hormones only
a causative role.
Endogenous hormone stimulation seems to play an im-
portant role in juvenile and pregnancy-induced mammary
hypertrophy, in which a rapid and massive enlargement of
the breasts occur. Subsequent pregnancies are likely to
cause further recurrence, once pregnancy-induced mam-
mary hypertrophy has occurred.
Yet in the majority of patients, it is not possible to iden-
tify a precipitating cause.
The main pathogenetic hypothesis of severe juvenile
and pregnancy-induced mammary hypertrophy are:
• An increase in serum level of estrogens, prolactin,
prostegerone, HGC, HLP, that could be associated to
anomalies in ovarian function or to malignancy (ovari-
an, adrenal, pituitary);
• An increase in free estrogen circulating levels, due to
reduction of sex binding globulin;
• Alterations in hormones hepatic catabolism;
• An increase in breast hormonal receptors sensibility or
number, with normal hormones serum level.
Hyperprolactinaemia has been associated with mamma-
ry hypertrophy, but its exact role is not absolutely clear. Not
all patients with hyperprolactinaemia present with breast
hypertrophy, but patients with pregnancy-induced gigan-
tomastia usually respond well to high dose of an anti-pro-
lactin agent such as bromocriptine. In contrast, breath en-
largement may not be arrested in patients with juvenile hy-
pertrophy and hyperprolactinaemia.
Another reported association is between hypercalcemia
and juvenile and pregnancy-induced hypertrophy, which
has been attributed to an excessive production of PTHrP
(parathyroid hormone-related protein). The reason for the
increase in PTHrP production that accompany pregnancy-
induced hypertrophy is yet not known.
In favor of the hypothesis of an altered hepatic metabo-
lism, one case of macromastia in an infant with Alagille’s
syndrome has been reported in literature, in which mamma-
ry hypertrophy was directly correlated to alterations in the
hepatic metabolism of estrogens, rather than to their hyper-
incretion under a gonadotropic stimulus, to the aromatiza-
tion of androgens or to central nervous system abnormalities.
Only a few studies exist on juvenile hypertrophy; while
much more data are available about pregnancy-induced
mammary hypertrophy.
To date any study has confirmed the more accredited
hypothesis, that of an increased responsiveness of breast
tissue to circulating hormones (receptor hypersensibility).
In literature, several cases of mammary hypertrophy
have been reported as adverse effect of a pharmacological
treatment. Some authors reported the onset of gigantomas-
tia after prolonged therapy with indinavir, a protease in-
ibitor, used in the treatment of HIV infection.
A Hiv-positive woman, one mounth after beginning a
triple therapy with lamivudine, stavudine and indinavir,
presented a rapid and progressive increase in breast vol-
ume, that regressed after discontinuation of indinavir
alone.
The importance of the role of indinavir for this particu-
lar case of gigantomastia is confirmed by several consider-
ations:
• Serum level of estrogens or prolactin are within the nor-
mal range;
• Indinavir frequently causes non specific morphological
changes of some body segments (e.g., abdominal glo-
bosity);
• Discontinuation of indinavir alone, while receiving the
other drugs, leads to a complete remission of the clini-
cal picture.
Another rare condition is gigantomastia in patients with
rheumatoid arthritis, receiving D-penicillamine. The first
case has been described by Desai in 1973.
It is likely that, reducing circulating levels of sex hor-
mon binding globulin, D-penicillamine, induces an in-
crease in serum levels of estrogens, thereby determining
mammary hypertrophy, or that, chelating zinc ions, sensi-
tizes breast tissue to the action of prolactin or other hor-
mones. A direct action on the mammary gland is also to be
considered. Discontinuation of D-penicillamine leads to an
arrest in breast growing.
A rare cause of mammary hypertrophy is Systemic Lu-
pus Erythematosus (SLE). In 1960 Shelley described a case
of severe bilateral mammary hypertrophy in a young
woman with positive SLE tests, diffuse annular erythema
and melanodermia.
Propper reported the case of a woman with SLE with
disease flare during pregnancy and breast hypertrophy
complicated by severe necrotic and ulcerated skin lesions,
probably attributable to cutaneous vasculitis. This condi-
tion resolved almost completely after delivery under
steroid therapy.
Both juvenile and pregnancy-induced mammary hyper-
trophy related to SLE have unclear etiologies; it is likely
that SLE may induce the production of substances that di-
rectly or indirectly, by mimicking the action of estrogen or
other growth factors, determine an increase in breast vol-
ume.
Obesity plays an important role in breast hypertrophy
pathogenesis; breast volume increases in all overweight
conditions, and it is not surprising that obese patients rep-
resent 2/3 of macromastia cases.
In literature it is reported that hypertrophic breast is
composed primarily of adipose and fibrous tissue, while
the glandular component remains essentially stable.
Lejour reported a mean of 48 percent fat by weight in
breast reduction specimens. She also observed that the
body mass index has more influence than age on the
amount of breast fat.
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This pathologic finding has also been highlighted by
Strömbeck, who proposed the term “macromastia” for pa-
tients requiring reduction mammaplasty, considering incor-
rect a diagnosis of “mammary hypertrophy”.
Several authors confirmed the importance of the fat
component in the enlarged breast, and reported their expe-
rience with liposuction as an integral part of surgical treat-
ment of macromastia.
TREATMENT
Reduction mammaplasty is the best therapeutic approach
for patients with mammary hypertrophy, for both physical
and psychological reasons. Its goal is to achieve a reduc-
tion of breast volume, while maintaining vascularization
and innervation of the nipple-areola complex, and limit-
ing scars.
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Fig. 19-2.Authors’ technique. A, Skin markings. B, Preoperative view of the patient. C, The superior pedicle. D, Wedge resection of the infe-
rior pole. E, Suture of the lateral pillars. F, Immediate postoperative view. G-H, One-year postoperative view of the patient.
A B
C D
E F
G H
The first attempts at reducing breast volume were pure-
ly functional, and it is only in the last century that aesthetic
considerations were taken into account.
Up to 1960, techniques of breast reduction were not
safe, because of extensive skin and glandular undermim-
ing. In 1957, Arie realized that it was preferable to avoid
any undermiming between skin and gland. In 1963, Skoog
proposed an inferoposterior resection and the transposition
of the nipple-areola complex on a laterally based dermal
pedicle flap, laying the basis for the development of mod-
ern reduction mammaplasty.
Since then, many surgical techniques have been got
ready, with an increasing interest in reducing scars’ lenght.
The choice of the technique depends on the size of the
breast, the degree of ptosis, the patient’s goal, and surgeon’s
preferences. The two main decisions that confront the sur-
geon are the choice of incision pattern, and the choice of pedi-
cle type, which are, for the most part, independent variables.
Different pedicle nipple-areola flap can be employed,
including a superior pedicle, an inferior pedicle, a vertical
bipedicle, a central mound pedicle, a lateral and a supero-
medial pedicle.
The incision pattern usually consist of a vertical or an
inverted-T scar, which can be applied to any pedicle type,
with the advantage of reducing scars’ length.
The choice of the pedicle usually depends on the need
for elevation of the nipple-areola complex, and the desire to
preserve sensory innervation or lactation.
AUTHORS’ TECHNIQUE
(Figure 19-2)
An accurate marking of the skin is made preoperatively,
which basically refers to Lejour’s vertical scar technique;
for this purpose the jugular notch is marked, together with
two points on the clavicle 5-6 cm at each side of it. A line
passing through the nipple is drawn from these points to the
inframammary fold (breast meridian).
The new nipple-areola complex position is drawn at the
intersection of the inframammary fold and the breast
meridian, that usually correspond to a distance of 19-22 cm
from the jugular notch, varying with patient height. The
areola region is marked with circular patterns on photo-
graphic film, obtaining a periareolar circumference of be-
tween 14 and 18 cm. In case of gigantomastia an elliptical
pattern of 18 cm is used.
The lateral margins of the area to be de-epithelialized
are marked by turning the breast in a clockwise direction
and counterclockwise, respectively. The lower edge of the
marking is obtained by combining the two lateral branches
with a circular arc passing 2-4 cm above the fold.
The lower breast quadrants are then infiltrated with
saline and adrenaline 1:100,000. Next, de-epithelitation of
the upper portion of the marked periareolar area is per-
formed, and extended about 4 cm inferiorly in order to
maintain the arterial and venous periareolar network; the
skin is dissected medially and laterally as necessary, and
the dissection is carried down to the fascial plane.
Once identified the fascial pre-pectoral plane, breast is
separated from the fascia of the pectoral muscle along a wide
central tunnel of about 8 cm, resection of the inferior pole and
of a wedge below the de-epithelialized area is performed.
The pedicle nipple-areola flap is then anchored high to
the chest and the two remaining medial and lateral pillars
are sutured to each other in order to reassemble the cone
breast. At this point, excess skin is evaluated and the direc-
tion of the scar is decided.
The remaining skin is defatted very carefully.
We found that in young patients with good skin retrac-
tion capability and for resection of up to 1 kg a simple ver-
tical scar can be used.
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Fig. 19-3. A 25-year-old pa-
tient. A-B, Preoperative view.
C-D, One-year postoperative
view (Authors’ technique).
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Rippled appearance of the scar is resolved within a few
weeks. In patients with flaccid skin and for resections of
over 1 kg with elevation of the nipple-areola complex of
over 10 cm, sometimes it is aesthetically more convenient
to make a L or T-inverted scar.
The final direction of the scars and the quantity of skin
to be removed are decided on a case by case basis (Figures
19-3 and 19-4).
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Fig. 19-4. A 28-year-old pa-
tient. A-B, Preoperative view.
C-D, Six months postopera-
tive view (Authors’ tech-
nique).
